Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020)

Cogent Biosciences has reported Current Deferred Revenue over the past 4 years, most recently at $312000.0 for Q2 2020.

  • Quarterly results put Current Deferred Revenue at $312000.0 for Q2 2020, down 97.94% from a year ago — trailing twelve months through Jun 2020 was $312000.0 (down 97.94% YoY), and the annual figure for FY2019 was $1.3 million, down 92.67%.
  • Current Deferred Revenue for Q2 2020 was $312000.0 at Cogent Biosciences, down from $841000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for COGT hit a ceiling of $20.4 million in Q2 2018 and a floor of $312000.0 in Q2 2020.
  • Median Current Deferred Revenue over the past 4 years was $15.2 million (2019), compared with a mean of $12.0 million.
  • Biggest five-year swings in Current Deferred Revenue: soared 160.47% in 2018 and later crashed 97.94% in 2020.
  • Cogent Biosciences' Current Deferred Revenue stood at $6.9 million in 2017, then soared by 160.47% to $17.9 million in 2018, then tumbled by 92.67% to $1.3 million in 2019, then plummeted by 76.27% to $312000.0 in 2020.
  • The last three reported values for Current Deferred Revenue were $312000.0 (Q2 2020), $841000.0 (Q1 2020), and $1.3 million (Q4 2019) per Business Quant data.